Quantum computing represents the next generation of powerful computing. A qubit processor is the most crucial hardware component of a quantum computer.
Archer is developing a qubit processor chip, that could potentially operate at room temperature and integrate into modern electronics.
Current quantum computing technologies are limited in ownership and use because they use qubit processors that can only operate at low temperatures and/or are difficult to integrate in modern electronics.
The successful development of Archer’s 12CQ room-temperature qubit processor chip could potentially provide a breakthrough solution to the widespread use and ownership of quantum computing powered technology, owing to the unique materials properties of the 12CQ chip.
The 12CQ qubit processor chip is being built by the Archer team in Sydney, Australia, in a world-class semiconductor foundry with an ISO Class 5 Level cleanroom housing state-of-art nanofabrication instrumentation. The work is led by Archer CEO and 12CQ inventor Dr Mohammad Choucair, and Archer’s Quantum Technology Manager Dr Martin Fuechsle, the inventor of the single-atom transistor. The 12CQ chip is based on work published in the prestigious journal Nature Communications, and patent application filed in Australasia, the EU, and US.
Australia has a critical mass of expertise in quantum computing and is at the forefront of the industry. There are currently very few publicly listed companies that offer exposure to financial returns from quantum computing technology.
The quantum computing industry forms a niche but quickly growing part of the global half-a-trillion-dollar semiconductor industry, which generates the highest value in investment returns through the step-change development of technology and underlying intellectual property.
Successful commercialisation of Archer’s 12CQ qubit processor chip technology could catalyse the global quantum computing industry by servicing existing and emerging consumer markets reliant on increased computational power like artificial intelligence (AI) and blockchain technologies like digital currencies.
Our strategy is to develop a qubit processor chip that can be directly sold and the intellectual property rights to the chip technology sublicensed by:
De-risking the technology by building a room-temperature operational qubit processor chip prototype. Development involves assembling and testing chip components by applying a deep understanding of nanotechnology, materials chemistry, and quantum physics.
Establishing partnerships with highly resourced organisations in the semiconductor industry. Commercial development involves prosecuting patent applications in Australasia, Europe and the US, to provide the commercial freedom to operate in these markets.
There is a global need for healthcare to become cheaper, efficient and more accessible. Archer’s A1 Biochip could enable rapid and customised multi-disease detection and aid point of care disease management.
Wide-spread scalable and economically manufactured biosensing technologies are hindered by the difficulty to achieve both effective multi-functional disease detection and efficient process integration.
Archer is developing the A1 Biochip, a lab-on-chip technology that incorporates graphene, the thinnest material known, to provide an ultrasensitive biochemical interface for multi-disease detection and compatibility with digitised processing for biosensor device integration.
Archer has filed patent applications protecting this intellectual property and maintains 100% ownership of the IP. The lab-on-chip technology is being developed at world-class institutes housing 2-D and 3-D prototype testing facilities and a world-class semiconductor foundry.
Australia has a critical mass of expertise in biotechnology and has made significant contributions to the industry. In Australia, Small-Medium-Enterprise companies could be eligible for a percentage cash refund of their annual R&D expenditure. There are currently about 150 publicly listed companies on the ASX in the Life Sciences sector.
The biosensing industry forms a niche but growing part of the global multibillion-dollar biotechnology industry, with established commercial pathways for high value investment returns through revenue generated from licensing of robust intellectual property portfolios.
Successful commercialisation of Archer’s lab-on-chip technology could catalyse the global biosensor industry by servicing the growing biomedical infrastructure of ageing populations in Europe, Australia, Asia, and the US, reliant on point-of-care health management.
Our strategy is to develop lab-on-chip componentry that can be patented and the intellectual property rights to the technology sublicensed by:
Developing a commercial prototype in-vitro diagnostic device by assembling and testing biochip components capable of rapid multi-disease detection and device integration.
Establishing partnerships with highly resourced organisations in the biotechnology industry. Commercial development involves prosecuting patent applications in Australasia, Europe and the US.